Direct oral anticoagulants for the treatment and prevention of venous thromboembolism in patients with cancer: current evidence

García-Escobar, I; Brozos-Vázquez, B; Gutierrez Abad, D; Martínez-Marín, V; Pachón, V; Muñoz Martín, A. J.
Clin. transl. oncol. (Print) ; 23(6): 1034-1046, jun. 2021. tab
Artículo en Inglés | IBECS (España) | ID: ibc-221324

Documentos relacionados

  1. Thromboembolism prophylaxis practices of pediatric and congenital electrophysiologists during invasive electrophysiology studies: A PACES survey.
  2. International recommendations for the prevention and treatment of venous thromboembolism associated with cancer.
  3. Low-Molecular-Weight Heparin Is Superior to Aspirin in the Prevention of Thromboembolic Disease: Or Is It?
  4. [Anticoagulants and cancer: beyond thromboembolic disease prevention].
  5. Direct oral anticoagulants in patients with nonvalvular atrial fibrillation and extreme body weight.
  6. Anticoagulation and antiplatelet therapy in patients with prosthetic heart valves.
  7. Deep vein thromboembolism in malignant diseases.
  8. Thromboembolic and hemorrhagic complications in patients with prosthetic heart valves cared for in a tertiary care center. What have we learned?
  9. Factor XI inhibition in hemodialysis patients: the safer anticoagulation?
  10. Low- or standard-dose edoxaban versus antiplatelet therapy for leaflet thrombus and cerebral thromboembolism after TAVR: A prespecified analysis of randomized ADAPT-TAVR trial.